000			01376nam a2200133Ia 4500
008			220620s9999||||xx |||||||||||||| ||und||
020			_a9783040000000
245		0	_aPharmacogenetics to Avoid Adverse Drug Reactions
546			_aEnglish[eng]
650			_a5-fluorouracil||capecitabine||fluoropyrimidine||thymidylate synthase||thymidylate synthase enhancer region||upstream stimulatory factor 1||adverse drug reactions||pharmacogenomics||epistasis||random forest||statin||cardiovascular disease||colorectal cancer||personalised medicine||toxicity||(es)citalopram||drug-gene-interaction||drug-drug-interaction||drug-drug-gene-interaction||the PharmLines initiative||antipsychotic agents||pharmacogenetics||cytochrome P-450 enzyme system||psychotic disorders||precision medicine||direct oral anticoagulants||clinical implementation||atorvastatin||SLCO1B1||HLA||cutaneous adverse drug reaction||SCAR||genetic polymorphism||antiepileptics||CYP450 enzymes||platelet reactivity||single-nucleotide variants||acute coronary syndrome||clopidogrel||genotype||allele||polymorphism||HLA B||CYP2C9*3||cutaneous adverse drug reactions (CADRs)||anti-epileptic drugs (AEDS)||phenytoin (PHT)||genetic risk factors||South India||India||cardiology||adverse events||guidelines||n/a
700			_aLópez-Fernández, Luis A.
856			_uhttps://mdpi.com/books/pdfview/book/5039
942			_cEB
999			_c31262 _d31262